Preventive and therapeutic significance of octreotide combined with lansoprazole on post‑ERCP pancreatitis and its effect on serum amylase, inflammatory factors and immune function

Abstract

The study aimed to investigate the preventive and therapeutic significance of octreotide combined with lansoprazole on post‑endoscopic retrograde cholangiopan‑ creatography (ERCP) pancreatitis (PEP) and its effects on serum amylase (AMS), inflammatory factors and immune function. A total of 132 patients who underwent ERCP in Shaoxing People's Hospital (Shaoxing, China) were enrolled in the study and allocated into two groups: The study group (octreotide plus lansoprazole, 68 cases) and the control group (octreotide alone, 64 cases). The incidence of PEP and post‑ERCP hyperamylasemia (PEH), the concentrations of serum AMS, interleukin‑17 (IL‑17) and tumor necrosis factor‑α (TNF‑α), as well as the T‑lymphocyte population in peripheral blood were detected. The AMS levels in the study group were significantly lower than those in the control group at 6 and 24 h after treatment (P<0.001). The incidence of PEP and PEH, symptom disappearance time and hospital stay in the study group were significantly lower than those in the control group after treatment (P<0.05). The levels of IL‑17 and TNF‑α in the study group were significantly lower than those in the control group after treatment (all P<0.05). The percentage of CD3+, CD4+, CD8+ cells and the ratio of CD4+/CD8+ in the study group were significantly higher than those in the control group after treatment (all P<0.05). The results indicated that octreotide combined with lansoprazole reduces AMS levels and the incidence of PEP, alleviates inflammation and improves the immune function.